FGF19 and hepatocellular carcinoma: Specifically, we chose analytes for serum biomarker analysis on the basis of the molecular targets (or ligands of the targeted receptors) of Lenvatinib, or those related to the outcome and/or pathogenesis of HCC, including VEGF, FGF19, FGF23, and Ang-2.